Difference between revisions of "Lee:Literature Proteasomes"

From OpenWetWare
Jump to: navigation, search
(Proteasome inhibitors in lung cancer)
Line 46: Line 46:
==Proteasome inhibitors in lung cancer==
==Proteasome inhibitors in lung cancer==
# Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR; Southwest Oncology Group. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2009 Jan;4(1):[http://ovidsp.tx.ovid.com/sp-3.2.4a/ovidweb.cgi?WebLinkFrameset=1&S=PPJLFPCPPHDDIMBBNCCLAHLBMAKAAA00&returnUrl=http%3a%2f%2fovidsp.tx.ovid.com%2fsp-3.2.4a%2fovidweb.cgi%3f%26Full%2bText%3dL%257cS.sh.15.17%257c0%257c01243894-200901000-00014%26S%3dPPJLFPCPPHDDIMBBNCCLAHLBMAKAAA00&directlink=http%3a%2f%2fgraphics.tx.ovid.com%2fovftpdfs%2fFPDDNCLBAHBBPH00%2ffs047%2fovft%2flive%2fgv024%2f01243894%2f01243894-200901000-00014.pdf&filename=Bortezomib+Plus+Gemcitabine%2fCarboplatin+as+First-Line+Treatment+of+Advanced+Non-small+Cell+Lung+Cancer%3a+A+Phase+II+Southwest+Oncology+Group+Study+%28S0339%29.&pdf_key=FPDDNCLBAHBBPH00&pdf_index=/fs047/ovft/live/gv024/01243894/01243894-200901000-00014 87-92].
==Proteasome inhibitors in pancreatic cancer==
==Proteasome inhibitors in pancreatic cancer==

Revision as of 08:14, 19 January 2011


Home                  Research                  Lab Members                  Publications                  JC                      Links                  Internal                  Contact                 

Feel free to add articles ...

Proteasome Biology general review

  1. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy.Nature. 2009 Mar 26;458(7237):438-44. (pmid=19325623)
  2. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005 Jul 20;23(21):4776-89. (pmid=16034054)
  3. Murata S, Yashiroda H, Tanaka K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol. 2009 Feb;10(2):104-15. (pmid=19165213)


  1. Fitzpatrick LR, Small JS, Poritz LS, McKenna KJ, and Koltun WA. Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease. Dis Colon Rectum. 2007 Mar;50(3):337-48; discussion 348-50. DOI:10.1007/s10350-006-0796-7 | PubMed ID:17160513 | HubMed [1]
  2. Gavilán MP, Castaño A, Torres M, Portavella M, Caballero C, Jiménez S, García-Martínez A, Parrado J, Vitorica J, and Ruano D. Age-related increase in the immunoproteasome content in rat hippocampus: molecular and functional aspects. J Neurochem. 2009 Jan;108(1):260-72. DOI:10.1111/j.1471-4159.2008.05762.x | PubMed ID:19012754 | HubMed [2]
  3. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, and Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009 May 7;113(19):4667-76. DOI:10.1182/blood-2008-07-171637 | PubMed ID:19050304 | HubMed [3]
  4. Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, and Kim KB. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol. 2007 Apr;14(4):419-30. DOI:10.1016/j.chembiol.2007.03.008 | PubMed ID:17462577 | HubMed [4]
  5. Heink S, Fricke B, Ludwig D, Kloetzel PM, and Krüger E. Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res. 2006 Jan 15;66(2):649-52. DOI:10.1158/0008-5472.CAN-05-2872 | PubMed ID:16423992 | HubMed [5]
  6. Namiki S, Nakamura T, Oshima S, Yamazaki M, Sekine Y, Tsuchiya K, Okamoto R, Kanai T, and Watanabe M. IRF-1 mediates upregulation of LMP7 by IFN-gamma and concerted expression of immunosubunits of the proteasome. FEBS Lett. 2005 May 23;579(13):2781-7. DOI:10.1016/j.febslet.2005.04.012 | PubMed ID:15907481 | HubMed [6]
  7. Mishto M, Bellavista E, Santoro A, Stolzing A, Ligorio C, Nacmias B, Spazzafumo L, Chiappelli M, Licastro F, Sorbi S, Pession A, Ohm T, Grune T, and Franceschi C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol Aging. 2006 Jan;27(1):54-66. DOI:10.1016/j.neurobiolaging.2004.12.004 | PubMed ID:16298241 | HubMed [7]
  8. Mishto M, Luciani F, Holzhütter HG, Bellavista E, Santoro A, Textoris-Taube K, Franceschi C, Kloetzel PM, and Zaikin A. Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics. J Mol Biol. 2008 Apr 11;377(5):1607-17. DOI:10.1016/j.jmb.2008.01.086 | PubMed ID:18336834 | HubMed [8]
  9. Mishto M, Bonafè M, Salvioli S, Olivieri F, and Franceschi C. Age dependent impact of LMP polymorphisms on TNFalpha-induced apoptosis in human peripheral blood mononuclear cells. Exp Gerontol. 2002 Jan-Mar;37(2-3):301-8. PubMed ID:11772516 | HubMed [9]
  10. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Störkel S, and Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer. 2004 Mar 20;109(2):265-73. DOI:10.1002/ijc.11681 | PubMed ID:14750179 | HubMed [10]
  11. Visekruna A, Joeris T, Schmidt N, Lawrenz M, Ritz JP, Buhr HJ, and Steinhoff U. Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: The proteasome pattern as diagnostic tool for IBD patients. Inflamm Bowel Dis. 2009 Apr;15(4):526-33. DOI:10.1002/ibd.20805 | PubMed ID:19067411 | HubMed [11]
  12. Tu L, Moriya C, Imai T, Ishida H, Tetsutani K, Duan X, Murata S, Tanaka K, Shimokawa C, Hisaeda H, and Himeno K. Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection. Eur J Immunol. 2009 Dec;39(12):3385-94. DOI:10.1002/eji.200839117 | PubMed ID:19830724 | HubMed [12]
  13. Vasuri F, Capizzi E, Bellavista E, Mishto M, Santoro A, Fiorentino M, Capri M, Cescon M, Grazi GL, Grigioni WF, D'Errico-Grigioni A, and Franceschi C. Studies on immunoproteasome in human liver. Part I: absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis. Biochem Biophys Res Commun. 2010 Jun 25;397(2):301-6. DOI:10.1016/j.bbrc.2010.05.104 | PubMed ID:20510670 | HubMed [13]
All Medline abstracts: PubMed | HubMed


  1. pmid=9419215
  2. pmid=12456675 (C-terminal Myc and FLAG tags for MECL, LMP2,Delta, Z)
  3. pmid=10329130 (modification of prepeptide sequence)
  4. pmid=10363659
  5. pmid=9321388 (GFP fusion)
  6. pmid=18728217
  7. pmid=19525961

Resistance mechanisms for proteasome inhibitors

  1. Giada Bianchi,Laura Oliva,Paolo Cascio,5 Niccolo Pengo,Francesca Fontana, Fulvia Cerruti, Andrea Orsi,Elena Pasqualetto, Alexandre Mezghrani, Valeria Calbi, Giovanni Palladini, Nicola Giuliani, Kenneth C. Anderson,Roberto Sitia,and Simone Cenci. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009 Mar 26;113(13):3040-9 : 3040-3049.(pmid=19164601)
  2. Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther. 2008 Aug;326(2):423-31. (pmid=18502982)
  3. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem. 2008 Jan 1;103(1):270-83. (pmid=17516511)

Proteasome inhibitors in lung cancer

  1. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR; Southwest Oncology Group. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2009 Jan;4(1):87-92.

Proteasome inhibitors in pancreatic cancer


  1. 1 pmid=16889756
  2. 2 pmid=16724054
  3. 3 pmid=17183360
  4. 4 pmid=16618413

MDR1 & apoptosis, NF-kB

  1. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, and Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003 Jan 9;22(1):90-7. DOI:10.1038/sj.onc.1206056 | PubMed ID:12527911 | HubMed [1]
  2. Pallis M and Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood. 2000 May 1;95(9):2897-904. PubMed ID:10779437 | HubMed [2]
  3. Smyth MJ, Krasovskis E, Sutton VR, and Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7024-9. PubMed ID:9618532 | HubMed [3]
  4. Johnstone RW, Cretney E, and Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999 Feb 1;93(3):1075-85. PubMed ID:9920858 | HubMed [4]
  5. Patel VA, Dunn MJ, and Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem. 2002 Oct 11;277(41):38915-20. DOI:10.1074/jbc.M206855200 | PubMed ID:12138126 | HubMed [5]
All Medline abstracts: PubMed | HubMed